What is Clinical Ink?
Founded in 2007 and headquartered in Horsham, Pennsylvania, Clinical Ink is dedicated to making clinical research more accessible for patients, sites, and sponsors. The company leverages its expertise across various therapeutic areas and employs advanced technologies such as Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers. These innovations are setting new industry standards for data precision and are ushering in a new era for clinical trials, aiming to streamline the research process and enhance data integrity.
How much funding has Clinical Ink raised?
Clinical Ink has raised a total of $54.5M across 6 funding rounds:
Private Equity
$3.1M
Series B
$4.3M
Private Equity
$20M
Other Financing Round
$20M
Series C
$5.4M
Debt
$1.7M
Private Equity (2011): $3.1M, investors not publicly disclosed
Series B (2013): $4.3M led by FCA Venture Partners
Private Equity (2015): $20M supported by Novartis AG and MPM Capital
Other Financing Round (2015): $20M featuring MPM Capital, F2 Ventures, and FCA Venture Partners
Series C (2016): $5.4M backed by Clayton Associates and FCA Venture Partners
Debt (2017): $1.7M, investors not publicly disclosed
Key Investors in Clinical Ink
MPM Capital
MPM Capital is a venture capital firm specializing in early-stage life sciences, managing funds focused on converting scientific breakthroughs into therapeutics for patients in need.
FCA Venture Partners
FCA Venture Partners, an investment arm of Clayton Associates, focuses on investing in start-up and early-stage companies, providing capital and mentorship to foster growth.
Novartis AG
Novartis AG is a global pharmaceutical company with a broad portfolio of innovative medicines, likely investing to align with advancements in clinical trial technology.
What's next for Clinical Ink?
With its substantial enterprise-level backing, Clinical Ink is poised for accelerated growth and further innovation. The company's focus on enhancing data precision and patient experience in clinical trials suggests a strategic direction towards expanding its technological offerings and market reach. Future developments are likely to center on deepening the integration of its digital solutions, potentially exploring new therapeutic applications, and solidifying its position as a leader in the next generation of clinical trial technology. This capital infusion will likely fuel research and development, enabling Clinical Ink to further refine its platform and address the evolving needs of the biopharmaceutical industry.
See full Clinical Ink company page
